PERCEPTIVE ADVISORS LLC - 10 Jan 2023 Form 4 Insider Report for Landos Biopharma, Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 10 Jan 2023
Net transaction value: +$16,690,909
SEC form: 4
Accepted by SEC: 11 Jan 2023, 17:45:00 UTC
Prior SEC filing: 21 Dec 2022
Next SEC filing: 06 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Joseph Edelman - for Perceptive Advisors LLC, By: Joseph Edelman, its managing member

Key filing fact

PERCEPTIVE ADVISORS LLC filed Form 4 for Landos Biopharma, Inc. on 11 Jan 2023.

Key facts

This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Landos Biopharma, Inc..
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 Jan 2023, 17:45.

Change

Previous filing in this sequence was filed on 21 Dec 2022.
Current net transaction value: +$16,690,909.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LABP transaction Derivative

Pre-funded Warrant

Purchase

Transaction value: $14,727,273
Shares: +27,272,727
Change %
Price: $0.5400
Shares after: 27,272,727
Date: 10 Jan 2023
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 27,272,727
Exercise price: $0.0100
Footnotes: F1, F2

LABP transaction Derivative

Pre-funded Warrant

Purchase

Transaction value: $1,963,636
Shares: +3,636,363
Change %
Price: $0.5400
Shares after: 3,636,363
Date: 10 Jan 2023
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 3,636,363
Exercise price: $0.0100
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Pre-Funded Warrants cannot be exercised to the extent that, upon giving effect to such exercise, the aggregated number of shares of Common Stock beneficially owned by the holder (together with its affiliates, any "group" or any other persons whose beneficial ownership could be aggregated with the holders) would exceed 35.00% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Footnote F2

The securities are directly held by Perceptive Xontogeny Venture Fund II, L.P. ("PXV II"). The Advisor serves as the investment manager of PXV II, and Perceptive Xontogeny Venture II GP, LLC ("PXV GP") is the general partner of PXV II. Mr. Edelman is the managing member of PXV GP and the Advisor. The Advisor, PXV GP and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Footnote F3

The securities are directly held by PX Venture (A), LLC ("PX Venture"). The Advisor serves as the investment manager of PX Venture, Mr. Edelman is the managing member of the Advisor. The Advisor, and Mr. Edelman disclaim, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his or its indirect pecuniary interest therein, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purposes.